RA AS HC Pvalue * Pvalue #
N 59 61 60    
Age (years), mean ± SEM 58 ± 1.6 43.6 ± 1.8 46.6 ± 1.8 < 0.0001 RA vs HC: < 0.0001
Gender (M/F), no. 12/47 46/15 13/47  **< 0.0001 AS vs HC: **< 0.0001
Disease duration (years), mean ± SEM 10.2 ± 1.1 11.7 ± 1.2 NA NS***  
Extra articular disease, no. (%)
Nodules 5 (8.4) 0 NA    
Uveitis 0 12 (19.6) NA    
Sicca syndrome 5 (8.4) 0 NA    
Crohn 0 4 (6.5) NA    
Psoriasis 0 8 (13.1) NA    
Rheumatoid Factors (%) 76.3 NA NA    
Anti-CPP antibodies (%) 76.3 NA NA    
HLA- B27 (%) NA 85.3 NA    
DAS28, mean ± SEM 3.9 ± 0.2 NA NA    
HAQ, mean ± SEM 1.14 ± 0.1 NA NA    
BASDAI, mean ± SEM NA 5.2 ± 0.3 NA    
BASFI, mean ± SEM NA 4.2 ± 0.3 NA    
ASDAS, mean ± SEM NA 3.2 ± 0.1 NA    
Treatments
MTX, no. (%) 33 (55.9)   NA    
LFM, no. (%) 10 (16.9)   NA    
Other (SLZ, HCQ), no. (%) 12 (20.3) 4 (6.5) NA    
AINS, no. (%)   44 (72.1) NA    
CTC, no. (dosage, m ean ± SEM) 33 (5.9 ± 2.8 mg) 5 (8.4 ± 2.3 mg) NA    
ESR (mm/h), mean ± SEM 26.6 ± 3.3 21.3 ± 2.9 13.5 ± 2.3 <0.05 RA vs HC: 0.0015
CRP (mg/L), mean ± SEM 12.2 ± 2.3 10.4 ± 2.1 5.7 ± 1.6 <0.0001 RA vs HC: 0.001 AS vs HC : < 0.0001
M: Male; F: Female; DAS28: Disease Activity Score 28 joints; HAQ: Health Assessment Questionnaire; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; ASDAS: Ankylosing Spondylitis Disease Activity Score; MTX: Methotrexate; LFM: Leflunomide; SLZ: Sulfasalazine; HCQ: Hydroxychloroquine; CTC: Corticosteroids; ESR: Erythrocyte
Sedimentation Rate; CRP: C-Reactive Protein
*Kruskal-Wallis test [level of significance was <0.05]
#post hoc Dunn test [level of significance was <0.016]
**Chi square test
***Mann-Whitney test). NA: not applicable
Table 1: Clinical and demographic characteristics of the patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and the healthy controls (HC).